AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33175470 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderated Nonlinear Factor Analysis (MNLFA) scale scoring
Number of subjects: 450
Study 33175470 — intervention group
Group type: COMPARATOR
Intervention: Symptom counts
Number of subjects: 450
Study 33175694 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital infographic intervention designed to increase trust in science
Number of subjects: 1000
Study 33175694 — intervention group
Group type: COMPARATOR
Intervention: Placebo-control
Number of subjects: 1000
Study 33175860 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI) method
Number of subjects: 15
Study 33175860 — intervention group
Group type: COMPARATOR
Intervention: Water perfused manometry
Number of subjects: 15
Study 33175877 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare professionals performing procedures that generated aerosols
Number of subjects: 1082
Study 33175877 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare professionals in emergency department and primary care units
Number of subjects: 1082
Study 33175877 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare professionals in public institutions
Number of subjects: 1082
Study 33175877 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall healthcare professionals
Number of subjects: 1082
Study 33175877 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific PPE shortages
Number of subjects: 1082
Study 33175911 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive autopsy (MIA)
Number of subjects: 18
Study 33175911 — intervention group
Group type: EXPERIMENTAL
Intervention: Histopathology
Number of subjects: 18
Study 33175911 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiology
Number of subjects: 18
Study 33175911 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiology
Number of subjects: 18
Study 33175911 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical review
Number of subjects: 18
Study 33176023 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care consultations
Number of subjects: 411931
Study 33176023 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist referrals
Number of subjects: 411931
Study 33176023 — intervention group
Group type: EXPERIMENTAL
Intervention: Emollient prescribing
Number of subjects: 411931
Study 33176023 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical corticosteroid prescribing
Number of subjects: 411931
Study 33176023 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment escalation
Number of subjects: 411931
Study 33176074 — intervention group
Group type: EXPERIMENTAL
Intervention: Subanesthetic intravenous ketamine combined with prolonged exposure therapy
Number of subjects: 0
Study 33176074 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33176443 — intervention group
Group type: EXPERIMENTAL
Intervention: Omecamtiv Mecarbil, dosage and duration not available
Number of subjects: 0
Study 33176546 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery on Monday to Wednesday
Number of subjects: 10576
Study 33176546 — intervention group
Group type: COMPARATOR
Intervention: Surgery on Thursday and Friday
Number of subjects: 10576
Study 33176546 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ≥ 6 points risk score
Number of subjects: 10576
Study 33176546 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with < 6 points risk score
Number of subjects: 10576
Study 33176546 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk patients (≥ 6 points) on Thursdays or Fridays
Number of subjects: 10576
Study 33176617 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-capsule bismuth quadruple therapy (proton pump inhibitor, bismuth, tetracycline, metronidazole), 3 capsules every 6 hours for 10 days
Number of subjects: 2100
Study 33176617 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-capsule bismuth quadruple therapy (first-line treatment)
Number of subjects: 2100
Study 33176617 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-capsule bismuth quadruple therapy (second-line treatment)
Number of subjects: 2100
Study 33176617 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-capsule bismuth quadruple therapy (third to sixth line treatment)
Number of subjects: 2100
Study 33176617 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-capsule bismuth quadruple therapy
Number of subjects: 2100
Study 33176718 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents aged 10-19 years
Number of subjects: 11501
Study 33176718 — intervention group
Group type: COMPARATOR
Intervention: Women aged 20-24 years (control group)
Number of subjects: 11501
Study 33176718 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced maternal age
Number of subjects: 11501
Study 33176736 — intervention group
Group type: EXPERIMENTAL
Intervention: Preeclampsia
Number of subjects: 73
Study 33176736 — intervention group
Group type: COMPARATOR
Intervention: Normotension
Number of subjects: 73
Study 33177132 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes, lung function, imaging and laboratory tests
Number of subjects: 800
Study 33177132 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival analysis using the Kaplan-Meier method
Number of subjects: 800
Study 33177139 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (MI) for fibromyalgia syndrome
Number of subjects: 0
Study 33177142 — intervention group
Group type: EXPERIMENTAL
Intervention: Potentially avoidable readmission within 30 days of discharge from index hospitalization.
Number of subjects: 1150
Study 33177223 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired body orientation (lateropulsion)
Number of subjects: 220
Study 33177223 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance and gait rehabilitation techniques
Number of subjects: 220
Study 33177887 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D Sonohysterography (3D SHG)
Number of subjects: 0
Study 33177887 — intervention group
Group type: COMPARATOR
Intervention: 2D Sonohysterography (2D SHG)
Number of subjects: 0
Study 33177997 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbosacral spinal cord epidural stimulation (CV-scES) applied for 97 sessions
Number of subjects: 1
Study 33178207 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2-specific T-cell polyfunctionality assessment against Spike and Nucleoprotein SARS-CoV-2 peptides for 5 patients.
Number of subjects: 15
Study 33178207 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring of lymphocyte subsets and total monocyte and subsets counts, and HLA-DR expression.
Number of subjects: 15
Study 33178207 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation of lymphopenia, monocyte numbers, and HLA-DR expression over time.
Number of subjects: 15
Study 33178384 — intervention group
Group type: EXPERIMENTAL
Intervention: 15% Lactic Acid and Ceramides
Number of subjects: 0
Study 33178384 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 33178408 — intervention group
Group type: EXPERIMENTAL
Intervention: Ravulizumab every 8 weeks (q8w)
Number of subjects: 243
Study 33178408 — intervention group
Group type: COMPARATOR
Intervention: Eculizumab followed by Ravulizumab
Number of subjects: 243
Study 33178447 — intervention group
Group type: EXPERIMENTAL
Intervention: Institution-based exercise plus self-management (SM)
Number of subjects: 0
Study 33178447 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management (SM) alone
Number of subjects: 0
Study 33178447 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 33178452 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification surgery in patients with NPDR
Number of subjects: 23
Study 33178452 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched nondiabetic patients)
Number of subjects: 23
Study 33178636 — intervention group
Group type: EXPERIMENTAL
Intervention: E6011 (humanized anti-FKN monoclonal antibody)
Number of subjects: 0
Study 33178765 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib combined with paclitaxel (PTX)
Number of subjects: 20
Study 33178765 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib combined with POF (PTX, oxaliplatin, and 5-fluorouracil)
Number of subjects: 20
Study 33178765 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib
Number of subjects: 20
Study 33178783 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive ventilation practices
Number of subjects: 100000
Study 33179149 — intervention group
Group type: EXPERIMENTAL
Intervention: CE-CT
Number of subjects: 34
Study 33179149 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 34
Study 33179341 — intervention group
Group type: EXPERIMENTAL
Intervention: Eczema incidence in infants younger than 1 year
Number of subjects: 3850000
Study 33179341 — intervention group
Group type: EXPERIMENTAL
Intervention: Eczema incidence in adults aged 40-49
Number of subjects: 3850000
Study 33179341 — intervention group
Group type: EXPERIMENTAL
Intervention: Eczema incidence in people 80 years or older
Number of subjects: 3850000
Study 33179341 — intervention group
Group type: EXPERIMENTAL
Intervention: Eczema prevalence in children aged 2
Number of subjects: 3850000
Study 33179341 — intervention group
Group type: EXPERIMENTAL
Intervention: Eczema prevalence in adults aged 30-39
Number of subjects: 3850000
Study 33179341 — intervention group
Group type: EXPERIMENTAL
Intervention: Eczema incidence in male infants (<2) and male adults older than 70
Number of subjects: 3850000
Study 33179341 — intervention group
Group type: EXPERIMENTAL
Intervention: Eczema incidence in females for all other ages
Number of subjects: 3850000
Study 33179341 — intervention group
Group type: EXPERIMENTAL
Intervention: Eczema incidence by ethnicity
Number of subjects: 3850000
Study 33179341 — intervention group
Group type: EXPERIMENTAL
Intervention: Eczema incidence by socio-economic status
Number of subjects: 3850000
Study 33179341 — intervention group
Group type: EXPERIMENTAL
Intervention: Eczema incidence and prevalence by geography
Number of subjects: 3850000
Study 33179591 — intervention group
Group type: EXPERIMENTAL
Intervention: Solriamfetol 75, 150, or 300 mg/day for ≤ 52 weeks
Number of subjects: 333
Study 33179845 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting glucagon-like peptide-1 receptor agonists (LA GLP-1RAs)
Number of subjects: 0
Study 33179845 — intervention group
Group type: EXPERIMENTAL
Intervention: DMC model
Number of subjects: 0
Study 33180023 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable device (activity tracker device, Garmin vívoactive 3)
Number of subjects: 0
Study 33180023 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline assessment and follow-up assessments
Number of subjects: 0
Study 33180026 — intervention group
Group type: EXPERIMENTAL
Intervention: REMOTION + psychotherapy
Number of subjects: 70
Study 33180026 — intervention group
Group type: COMPARATOR
Intervention: Psychotherapy alone (treatment-as-usual)
Number of subjects: 70
Study 33180106 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of TKIs
Number of subjects: 172
Study 33180106 — intervention group
Group type: COMPARATOR
Intervention: Restarting a TKI
Number of subjects: 172
Study 33180174 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation treatment
Number of subjects: 80
Study 33180550 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33180905 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory Blood Pressure Monitoring (ABPM)
Number of subjects: 52
Study 33181648 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrointestinal microbiota composition analysis in fetuses with FGR
Number of subjects: 126
Study 33181648 — intervention group
Group type: COMPARATOR
Intervention: Gastrointestinal microbiota composition analysis in fetuses with appropriate growth
Number of subjects: 126
Study 33181832 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ibrutinib, obinutuzumab, and venetoclax (venetoclax at 400 mg per day).
Number of subjects: 48
Study 33181832 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of ibrutinib, obinutuzumab, and venetoclax.
Number of subjects: 48
Study 33183159 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33183312 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with CHD
Number of subjects: 124
Study 33183312 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 124
Study 33183312 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents of children with CHD
Number of subjects: 124
Study 33183322 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased CSF levels of ficolin-1
Number of subjects: 0
Study 33183322 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased CSF levels of MBL
Number of subjects: 0
Study 33183322 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF levels of ficolin-1 and MBL in patients who developed DCI
Number of subjects: 0
Study 33183322 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF levels of ficolin-2 and ficolin-3
Number of subjects: 0
Study 33183322 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma ficolin-1 and ficolin-3
Number of subjects: 0
Study 33183322 — intervention group
Group type: EXPERIMENTAL
Intervention: DCI and functional outcome
Number of subjects: 0
Study 33183506 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Percutaneous Coronary Intervention (PPCI) in 2020 during the COVID-19 pandemic
Number of subjects: 6609
Study 33183506 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with arterial hypertension
Number of subjects: 6609
Study 33183506 — intervention group
Group type: EXPERIMENTAL
Intervention: Door-to-balloon and total ischemia times during the pandemic
Number of subjects: 6609
Study 33183506 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment impact during the pandemic
Number of subjects: 6609
Study 33183563 — intervention group
Group type: EXPERIMENTAL
Intervention: Diverting ileostomy group (n = 41)
Number of subjects: 78
Study 33183563 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 37)
Number of subjects: 78
Study 33183568 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 21
Study 33183568 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous protein intake post-surgery
Number of subjects: 21
Study 33184050 — intervention group
Group type: EXPERIMENTAL
Intervention: RhoC-derived 20mer peptide vaccine (0.1 mg, subcutaneous injections every 2 weeks for the first 6 doses, then every 4 weeks for a total of 30 weeks)
Number of subjects: 22
Study 33184050 — intervention group
Group type: EXPERIMENTAL
Intervention: RhoC-derived 20mer peptide vaccine
Number of subjects: 22
Study 33184069 — intervention group
Group type: EXPERIMENTAL
Intervention: Clot burden score (smaller clots)
Number of subjects: 326
Study 33184069 — intervention group
Group type: EXPERIMENTAL
Intervention: FLAIR vascular hyperintensity score (better collaterals)
Number of subjects: 326
Study 33184069 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction of clot burden score and FLAIR vascular hyperintensity score
Number of subjects: 326
Study 33184069 — intervention group
Group type: EXPERIMENTAL
Intervention: FLAIR vascular hyperintensity score as a prognostic factor
Number of subjects: 326
Study 33184081 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D status assessment
Number of subjects: 0
Study 33184088 — intervention group
Group type: EXPERIMENTAL
Intervention: RECAP-V0 early warning score
Number of subjects: 162
Study 33184120 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised saline
Number of subjects: 0
Study 33184120 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 33184150 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfonylureas
Number of subjects: 24
Study 33184152 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise testing (CPX) on a cycle ergometer in individuals with type 1 diabetes
Number of subjects: 303
Study 33184152 — intervention group
Group type: COMPARATOR
Intervention: Control participants without type 1 diabetes
Number of subjects: 303
Study 33184230 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelial microvesicles (EMV)
Number of subjects: 571
Study 33184230 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte-derived microvesicles (LMV)
Number of subjects: 571
Study 33184230 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-derived microvesicles (PMV)
Number of subjects: 571
Study 33184230 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocytic microvesicles (MMV)
Number of subjects: 571
Study 33184420 — intervention group
Group type: EXPERIMENTAL
Intervention: High resolution anorectal manometry (HRAM)
Number of subjects: 25
Study 33184685 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi-phasic, biodegradable, and cell-free aragonite-based scaffold (Agili-C™)
Number of subjects: 20
Study 33184967 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment for 8 weeks
Number of subjects: 138
Study 33185490 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid technique with a novel device for microtia repair
Number of subjects: 0
Study 33185490 — intervention group
Group type: COMPARATOR
Intervention: Temporoparietal fascia over polypropylene implants
Number of subjects: 0
Study 33186055 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 patients with troponin levels under the upper limit of normal
Number of subjects: 243
Study 33186055 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 patients with troponin levels >10 times the upper limit of normal
Number of subjects: 243
Study 33186055 — intervention group
Group type: COMPARATOR
Intervention: COVID-19 patients
Number of subjects: 243
Study 33186055 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical factors associated with myocardial injury
Number of subjects: 243
Study 33186201 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) program, 10, 1-min high-intensity cycling intervals interspersed with 1-min recovery intervals, performed 3 days/week for 6 weeks.
Number of subjects: 30
Study 33186201 — intervention group
Group type: COMPARATOR
Intervention: Usual-care supervised exercise program
Number of subjects: 30
Study 33186237 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban administered via PEG
Number of subjects: 12
Study 33186310 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung recruitment manoeuvre (LRM) with continuous inspiratory pressure of 25 cmH2O for 20 seconds
Number of subjects: 30
Study 33186310 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung recruitment manoeuvre (LRM)
Number of subjects: 30
Study 33186310 — intervention group
Group type: COMPARATOR
Intervention: Respiratory variation of pulse oximetry photoplethysmographic waveform and pulse pressure variation
Number of subjects: 30
Study 33186471 — intervention group
Group type: EXPERIMENTAL
Intervention: Next-generation sequencing investigating 740 hotspot somatic mutations in 46 genes involved in carcinogenesis.
Number of subjects: 347
Study 33186517 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored clinical practice guidelines from participating centres
Number of subjects: 1329
Study 33186517 — intervention group
Group type: COMPARATOR
Intervention: NICE guidelines CG102
Number of subjects: 1329
Study 33186517 — intervention group
Group type: COMPARATOR
Intervention: NICE guidelines NG51
Number of subjects: 1329
Study 33186517 — intervention group
Group type: EXPERIMENTAL
Intervention: London clinical practice guidelines
Number of subjects: 1329
Study 33186517 — intervention group
Group type: EXPERIMENTAL
Intervention: Nottingham clinical practice guidelines
Number of subjects: 1329
Study 33186617 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined external beam radiation therapy (45 Gy in 25 fractions) and HDR brachytherapy (19 Gy in 2 fractions)
Number of subjects: 129
Study 33186617 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined external beam radiation therapy and HDR brachytherapy
Number of subjects: 129
Study 33186669 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT)
Number of subjects: 2289
Study 33186783 — intervention group
Group type: EXPERIMENTAL
Intervention: High Urinary Symptoms Profile (USP) score related to overactive bladder
Number of subjects: 154
Study 33186783 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe nocturia (>2 nocturnal micturitions)
Number of subjects: 154
Study 33186783 — intervention group
Group type: COMPARATOR
Intervention: Presence of urinary incontinence
Number of subjects: 154
Study 33186783 — intervention group
Group type: COMPARATOR
Intervention: Type or severity of urinary symptoms (overactivity, voiding dysfunction, stress incontinence)
Number of subjects: 154
Study 33187477 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary behavior assessment prior to surgery
Number of subjects: 38
Study 33187477 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery-induced rise in circulating IL-6 levels
Number of subjects: 38
Study 33187477 — intervention group
Group type: EXPERIMENTAL
Intervention: HMGB1 levels measured preoperatively and at 6 and 24 hours post-surgery
Number of subjects: 38
Study 33187477 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini Mental State Examination (MMSE) preoperatively and at 6 weeks and 3 months post-surgery
Number of subjects: 38
Study 33187482 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine supplementation (150-200 µg daily) during preconception, pregnancy, and lactation
Number of subjects: 304
Study 33187482 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine supplementation (150-200 µg daily)
Number of subjects: 304
Study 33187482 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum thyroid-hormone parameters in the 1st trimester of pregnancy
Number of subjects: 304
Study 33187749 — intervention group
Group type: EXPERIMENTAL
Intervention: Postimplementation of pediatric traumatic brain injury guidelines
Number of subjects: 2801
Study 33187749 — intervention group
Group type: EXPERIMENTAL
Intervention: Postimplementation of pediatric traumatic brain injury guidelines in severe traumatic brain injury cohort
Number of subjects: 2801
Study 33187749 — intervention group
Group type: EXPERIMENTAL
Intervention: Postimplementation of pediatric traumatic brain injury guidelines in severe traumatic brain injury with positive-pressure ventilation
Number of subjects: 2801
Study 33187749 — intervention group
Group type: COMPARATOR
Intervention: Preimplementation of pediatric traumatic brain injury guidelines
Number of subjects: 2801